MarketInOut Stock Screener Log In | Sign Up
 

Compass Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Compass Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization150.07 mln
Float137 mln
Earnings Date11/11/2026

Piotroski F-Score

3 / 9
Below average

1-Year Forecast

5.45
Transformational upside

Relative Strength

10 / 100
Significantly lagging

Debt / Equity

0.06
Debt-free

ROE

-43.10
Deeply negative

ROA

-38.04
Deeply negative

Business Description

Compass Therapeutics is a Boston-based clinical-stage company focused on developing antibody-based treatments for cancer. Its lead drug candidate, tovecimig, works by blocking two proteins that tumors rely on to build their blood supply, potentially cutting off the resources cancer cells need to grow and spread. The company is also advancing several other experimental treatments designed to help the immune system recognize and attack cancer more effectively. Founded in 2014, Compass Therapeutics is working to build a broad portfolio of therapies that address some of the most challenging aspects of treating cancer.

Key Fundamentals

EPS-0.39
ROE-43.10
ROIC-604
ROA-38.04
EBITDA, mln-71.96
EV / EBITDA-0.44
EV / EBIT-0.43

Quote Details

Last 0.761
Change -0.0405 (-5.05%)
Open 0.7805
Volume 2,126,238
Turnover 1,618,067
Average Volume 5,370,584

Financial Ratios

Leverage Ratio1.15
Current Ratio11.22
Price / Book1.13
Price / Tangible Book1.13
Debt / Equity0.06

Financial Strength

Piotroski F-Score 3 / 9
1-Year Target Price5.45
Short Ratio8.74
Short % of Float26.79

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -11.51% 7 / 100   
1 Month -33.25% 10 / 100   
2 Months -62.33% 5 / 100   
6 Months -84.87% 3 / 100   
1 Year -81.71% 8 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog